2023 World Conference on Lung Cancer (Posters)-EP10.01. A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC

EP10.01. A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC - PDF(Slides)

Back to course

Pdf Summary

This is a summary of a poster presentation by Alexander Drilon from Memorial Sloan Kettering Cancer Center in the USA. The study focuses on the use of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with MET-overexpressing non-small cell lung cancer (NSCLC). The MET receptor is associated with poor prognosis in NSCLC and other cancers. REGN5093-M114 is a bispecific antibody that binds to two distinct epitopes of MET, blocking its interaction with hepatocyte growth factor (HGF) and leading to its degradation. REGN5093-M114 also contains a cytotoxic payload that is released upon degradation of the MET-REGN5093-M114 complex. In preclinical models, REGN5093-M114 demonstrated significant anti-tumor activity in MET-overexpressing cancers. <br /><br />The study aims to evaluate the safety, pharmacokinetics, and efficacy of REGN5093-M114 in patients with MET-overexpressing NSCLC. The study design includes a dose escalation phase and a dose expansion phase. The primary objectives are to determine the maximum tolerated dose or recommended Phase 2 dose of REGN5093-M114 and to assess the preliminary anti-tumor activity. Secondary objectives include evaluating immunogenicity, safety, and pharmacokinetics of REGN5093-M114. Exploratory objectives include evaluating subgroups associated with clinical response based on different MET scoring methods and assessing the relationship between clinical response and MET alterations.<br /><br />The study has enrolled 18 patients across five dose levels as of June 2023. The authors highlight the unmet need for patients with MET-altered advanced NSCLC and the potential of REGN5093-M114 to address this need. The study is currently open for enrollment and actively recruiting patients. The authors acknowledge the support from investigators, patients, and Regeneron Pharmaceuticals, Inc., which funded the study.

Asset Subtitle

Alexander Drilon

Meta Tag

Speaker Alexander Drilon

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

REGN5093-M114

MET-overexpressing non-small cell lung cancer

MET receptor

bispecific antibody

hepatocyte growth factor

anti-tumor activity

dose escalation phase

pharmacokinetics

clinical response

MET alterations